New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™-Itraconazole, Inhibiting the Hedgehog Signaling Pathway
INHIBITOR to Hold End of Phase 2 Meeting with FDA in Q4 2019 Prior to Filing IND for Phase 2b Clinical Trial of SUBA-Itraconazole in Prostate Cancer
INHIBITOR Renews and Expands Exclusive Worldwide Option Agreement with the University of Connecticut for Novel Compounds that Inhibit Upstream Targets of the Hedgehog Pathway
PR Newswire
TAMPA, Fla., Aug. 19, 2019